RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor

Italia Bongarzone, Cristiana Carniti, Carla Perego, Piera Mondellini, Marco Alessandro Pierotti

Research output: Contribution to journalArticle

Abstract

Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.

Original languageEnglish
Pages (from-to)550-552
Number of pages3
JournalTumori
Volume89
Issue number5
Publication statusPublished - Sep 2003

    Fingerprint

Keywords

  • Medullary thyroid cancer pathogenesis
  • MEN 2A
  • MEN 2B
  • PP1 inhibitor
  • RET oncoproteins

ASJC Scopus subject areas

  • Cancer Research

Cite this

Bongarzone, I., Carniti, C., Perego, C., Mondellini, P., & Pierotti, M. A. (2003). RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor. Tumori, 89(5), 550-552.